Abstract
BackgroundDeregulated signal transducer and activator of transcription 3 (STAT3) signaling has been well documented in certain cancers. Alterations in specific negative regulators, such as protein inhibitor of activated STAT3 (PIAS3), may contribute to cancer development.MethodsThe expression of total PIAS3 was determined in 100 paired cancerous and non-cancerous breast tissues by immunoblotting and was statistically analyzed along with the clinicopathological characteristics and overall survival of the patients. XTT, immunoblotting, and chromatin immunoprecipitation (Chip) were used to examine the biological effect of PIAS3 in breast cancer cells.ResultsHormone therapy failed to improve the overall survival in patients presenting with increased PIAS3 expression. Ectopic PIAS3 overexpression increased the proliferation and expression of cyclin D1 in estrogen receptor (ER)-positive MCF-7 and T47D cells, but decreased those in ER-negative MDA-MB-231 and SKBR3 cells. Furthermore, PIAS3 overexpression attenuated cytotoxicity of tamoxifen and increased proliferation and cyclin D1 expression in MCF-7 cells. PIAS3 also decreased the binding of itself on the cyclin D1 promoter and this decreased binding was not affected by tamoxifen.ConclusionPIAS3 may serve as a biomarker for predicting hormone therapy stratification, although it is limited to those breast cancer patients receiving hormone therapyElectronic supplementary materialThe online version of this article (doi:10.1186/s12885-016-2063-1) contains supplementary material, which is available to authorized users.
Highlights
Deregulated signal transducer and activator of transcription 3 (STAT3) signaling has been well documented in certain cancers
protein inhibitor of activated STAT3 (PIAS3) expression levels were normalized to the levels of the corresponding β-actin protein
Deregulated STAT3 signaling has been associated with breast cancer [9, 19] and alterations in PIAS3 may play a role in breast cancer
Summary
Deregulated signal transducer and activator of transcription 3 (STAT3) signaling has been well documented in certain cancers. Alterations in specific negative regulators, such as protein inhibitor of activated STAT3 (PIAS3), may contribute to cancer development. Deregulated Janus-activated kinase (JAK)/signal transducer and activator of transcription (STAT) signaling has been closely associated with various human diseases. In this pathway, STAT3 is the most recognized oncogene and frequently is activated in human cancers [1]. Aberrations in a specific STAT3 regulator such as the protein inhibitor of activated STAT3 (PIAS3) may contribute to cancer development [2]. Positive p-tyr705-STAT3 nuclear expression has been shown to be an independent prognostic marker of better overall survival in node-negative breast cancer using multivariate analyses. Other studies have suggested that tyrosine 705 phosphorylation of STAT3 is a
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
